Please ensure Javascript is enabled for purposes of website accessibility

Why MacroGenics Stock Is Tumbling Today

By Keith Speights - May 20, 2021 at 11:52AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company announced preliminary phase 1 results for its tumor-fighting drug MGC018.

What happened

Shares of MacroGenics (MGNX 3.65%) were tumbling 5.7% lower as of 11:39 a.m. EDT on Thursday. The decline came after the company announced preliminary results from its phase 1 study evaluating MGC018 in treating solid tumors.

So what

MacroGenics said that it saw preliminary signals of anti-tumor activity with MGC018 in treating patients with advanced metastatic castration-resistant prostate cancer (mCRPC). The company reported that reductions in prostate-specific antigens (PSAs) of at least 50% were observed in five patients. Of the nine patients in the study with mCRPC, eight demonstrated stable disease. 

Man in a lab coat looking through a microscope with a woman in a lab coat standing in the background.

Image source: Getty Images.

The company also stated that three patients with melanoma were given a 4.0 mg/kg dose of MGC018. One of these patients had a confirmed partial response with a 36% target lesion sum reduction.

MacroGenics reported that blood and skin toxicities related to MGC018 have been "clinically manageable." In the dose-escalation part of the phase 1 study, 27 of the 29 patients experienced at least one treatment-related adverse event. 

Investors seem to have hoped for better results based on the performance of the biotech stock today.

Now what

MacroGenics now plans to share the full data from its phase 1 study of MGC018 at the American Society of Clinical Oncology annual meeting in early June. The company also expects to provide additional updates at other scientific conferences.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

MacroGenics, Inc. Stock Quote
MacroGenics, Inc.
$4.55 (3.65%) $0.16

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.